The latest announcement is out from Jinhai International Group Holdings Limited ( (HK:2225) ).
Jinhai Medical Technology Limited announced its audited consolidated results for the year ended December 31, 2024. The company reported a revenue increase to S$50,241,000 from S$45,644,000 in 2023. However, the company faced a significant net loss of S$18,255,000, compared to a loss of S$4,112,000 in the previous year. The increase in administrative expenses and finance costs contributed to the widened loss. The announcement indicates challenges in managing costs, which may impact the company’s financial stability and investor confidence.
More about Jinhai International Group Holdings Limited
Jinhai Medical Technology Limited operates in the medical technology industry, focusing on providing innovative medical solutions. The company is listed on the Main Board of the Stock Exchange and has been operational since its listing in October 2017.
YTD Price Performance: -27.37%
Average Trading Volume: 4,514,817
Technical Sentiment Signal: Sell
Current Market Cap: HK$7.13B
For a thorough assessment of 2225 stock, go to TipRanks’ Stock Analysis page.